Published: Thursday, December 11, 2025 OKLAHOMA CITY The success of GLP-1 medications for treating Type 2 diabetes and obesity naturally leads to a related question: Do GLP-1 drugs affect cancer risk, which is often associated with obesity and Type 2 diabetes
Importantly, lean tissue has a higher metabolic rate than adipose tissue, and its preservation is critical for sustaining metabolic health, physical function, and long-term weight maintenance
Personalized treatment is important, as age, sex, and even lifestyle can change how someone reacts to retatrutide
In the ongoing quest to achieve not merely longer lives but healthier, more vibrant lives, Retatrutide is emerging as a groundbreaking therapeutic frontier in obesity medicine and longevity care
The Results In this study, 3,346 people with obesity, meaning a BMI over 30, but without diabetes started GLP-1 therapy and were compared to 8,343 similar people not using GLP-1 drugs
In one of the studies, patients with a mean baseline body mass index (BMI) of 35.3 kg/m and an average HbA1c of 8.3% were randomized to receive varying doses of GLP-3 (ranging from 1 mg to 12 mg) or placebo over a 36-week study period
